Skip to content
ModernDoc
Get the app
Condition research / Explore another topicSaved preview · Not clinically reviewed
Crohn disease.

The long view. The new questions.
A clearer understanding.

A deeper look at the research on Crohn disease.
For you. For someone you love. For the questions that keep coming.

4 saved articles · AI-written
Not clinically reviewed

The cover story · 2026 Oct

Early endoscopy-score changes were linked to delayed response

This post-hoc analysis followed people with moderate-to-severe Crohn’s disease who received upadacitinib and had not responded by week 12. Among those with week 24 data, delayed response was less common without an early reduction in a modified endoscopy score. The score was associated with later response but was not tested as a decision-making strategy. All participants received upadacitinib, and the extension was open-label; this analysis does not establish the extension’s benefit against another strategy. The delayed-response findings apply to 122 initial nonresponders with week 24 data, not all 194 initial nonresponders. Response was assessed through week 24, so later outcomes are not established. This was a post-hoc association analysis; it did not test whether using the score to guide treatment decisions improves outcomes.

Read the story ↗

Research readings

A closer reading.

Study readings

Early endoscopy-score changes were linked to delayed response

This post-hoc analysis followed people with moderate-to-severe Crohn’s disease who received upadacitinib and had not responded by week 12. Among those with week 24 data, delayed response was less common without an early reduction in a modified endoscopy score. The score was associated with later response but was not tested as a decision-making strategy. All participants received upadacitinib, and the extension was open-label; this analysis does not establish the extension’s benefit against another strategy. The delayed-response findings apply to 122 initial nonresponders with week 24 data, not all 194 initial nonresponders. Response was assessed through week 24, so later outcomes are not established. This was a post-hoc association analysis; it did not test whether using the score to guide treatment decisions improves outcomes.

2 min read · 2026 Oct

Study readings

Nurse-led pilot improved functioning while symptoms changed little

Adults with inflammatory bowel disease and ongoing symptoms received either usual care or online self-management modules with weekly nurse calls. Compared with usual care, the program produced larger improvements in functional impairment, patient activation, self-regulation and quality of life. Symptom severity and fecal calprotectin were largely unchanged. The cohort included ulcerative colitis and Crohn’s disease and was 76.4% women; it does not establish the same result for all people with Crohn’s disease. This was a 55-participant pilot, so its preliminary estimates need confirmation in a fully powered trial. Outcomes beyond the 6-month follow-up are not established.

2 min read · 2026 Nov

Study readings

Early top-down treatment was linked to fewer surgeries

People with newly diagnosed Crohn’s disease were assigned to early infliximab plus an immunomodulator or a conventional step-up strategy. During follow-up, abdominal surgery was recorded in six top-down patients and 26 step-up patients. Hospital admission and disease progression were also less frequent after top-down treatment. The randomized strategies lasted 48 weeks; afterward, treatment followed local standards, so the later comparison reflects original assignment rather than continued randomized protocols. Participants were aged 16–80 years, newly diagnosed and treated in the UK, so the study does not establish the same results in every Crohn’s disease population. Median follow-up was approximately 5 years, so outcomes beyond that period are not established. No difference was observed for serious infections or malignancies, but this does not establish identical safety between strategies.

2 min read · 2026 Nov

Study readings

Matched pediatric groups showed no clear 12-month differences

Researchers retrospectively matched children with inflammatory bowel disease who started original infliximab or a biosimilar. At 12 months, measured remission, growth, laboratory, treatment-discontinuation, surgery and hospitalization outcomes showed no statistically significant differences between groups. Because this was a retrospective matched comparison, it does not prove the products are equivalent. This retrospective matched study was not randomized, and a lack of statistically significant differences does not establish that the products are equivalent. The cohort included children with inflammatory bowel disease rather than a Crohn’s-only group, so it does not establish a Crohn’s-specific result or an adult result. Only 30% of patients had fecal calprotectin values, limiting certainty for that particular comparison. Clinical outcomes were assessed at 12 months, so later outcomes are not established.

2 min read · 2026 Oct

Follow your curiosity.

4 articles

Study readings

Early endoscopy-score changes were linked to delayed response

This post-hoc analysis followed people with moderate-to-severe Crohn’s disease who received upadacitinib and had not responded by week 12. Among those with week 24 data, delayed response was less common without an early reduction in a modified endoscopy score. The score was associated with later response but was not tested as a decision-making strategy. All participants received upadacitinib, and the extension was open-label; this analysis does not establish the extension’s benefit against another strategy. The delayed-response findings apply to 122 initial nonresponders with week 24 data, not all 194 initial nonresponders. Response was assessed through week 24, so later outcomes are not established. This was a post-hoc association analysis; it did not test whether using the score to guide treatment decisions improves outcomes.

2 min read · 2026 Oct

Study readings

Nurse-led pilot improved functioning while symptoms changed little

Adults with inflammatory bowel disease and ongoing symptoms received either usual care or online self-management modules with weekly nurse calls. Compared with usual care, the program produced larger improvements in functional impairment, patient activation, self-regulation and quality of life. Symptom severity and fecal calprotectin were largely unchanged. The cohort included ulcerative colitis and Crohn’s disease and was 76.4% women; it does not establish the same result for all people with Crohn’s disease. This was a 55-participant pilot, so its preliminary estimates need confirmation in a fully powered trial. Outcomes beyond the 6-month follow-up are not established.

2 min read · 2026 Nov

Study readings

Early top-down treatment was linked to fewer surgeries

People with newly diagnosed Crohn’s disease were assigned to early infliximab plus an immunomodulator or a conventional step-up strategy. During follow-up, abdominal surgery was recorded in six top-down patients and 26 step-up patients. Hospital admission and disease progression were also less frequent after top-down treatment. The randomized strategies lasted 48 weeks; afterward, treatment followed local standards, so the later comparison reflects original assignment rather than continued randomized protocols. Participants were aged 16–80 years, newly diagnosed and treated in the UK, so the study does not establish the same results in every Crohn’s disease population. Median follow-up was approximately 5 years, so outcomes beyond that period are not established. No difference was observed for serious infections or malignancies, but this does not establish identical safety between strategies.

2 min read · 2026 Nov

Study readings

Matched pediatric groups showed no clear 12-month differences

Researchers retrospectively matched children with inflammatory bowel disease who started original infliximab or a biosimilar. At 12 months, measured remission, growth, laboratory, treatment-discontinuation, surgery and hospitalization outcomes showed no statistically significant differences between groups. Because this was a retrospective matched comparison, it does not prove the products are equivalent. This retrospective matched study was not randomized, and a lack of statistically significant differences does not establish that the products are equivalent. The cohort included children with inflammatory bowel disease rather than a Crohn’s-only group, so it does not establish a Crohn’s-specific result or an adult result. Only 30% of patients had fecal calprotectin values, limiting certainty for that particular comparison. Clinical outcomes were assessed at 12 months, so later outcomes are not established.

2 min read · 2026 Oct

A publication for curiosity.

AI-written. Not clinically reviewed. Selected sources, not a complete review. No personal treatment matching.

Article revisions preserve earlier writing. Article dates and source-check dates describe different events. Email updates and automatic research refresh are unavailable during this pilot.